BOT, page-132

Mangement certainly ramping this company to the max which is great but why?
No need for a capital raise at least until the the BTX 1308 Psoriasis results are out.
Directors have skin in the game so dilution for them is a big negative which is why I was suprised they had the capital raise for BTX 1204 Dermatitis.
 
Unlike other drug treatments for cancer etc our team can ‘see’ the results daily : the following senarios for BTX 1503  may or may not have happened in real life 

Doctor 1 - What side effects are you experiencing?
Patient 1 - SFA

Doctor 2 - Hi xyx, where the hell has your acne gone?
Patient 2 - I guess I’m not taking the placebo!

My point here is that the results are obvious to management but they have to choose their words wisely.

Reality Check : We have 761 million shares on issue is all relative so those looking to the $1 share price is not realistic any time soon but a longer term holders  think Cochlear